Serum calprotectin elevation and interferon-α-induced neutrophil priming in macrophage activation syndrome associated with systemic lupus erythematosus: Clinical and experimental insights
Open Access
- 24 February 2026
- journal article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (5) , 778-785
Abstract
Objectives: To clarify the diagnostic utility of serum calprotectin and gene expression in interferon (IFN)-α-activated neutrophils in macrophage activation syndrome (MAS) in patients with systemic lupus erythematosus (SLE). Methods: This single-centre, cross-sectional study analysed serum calprotectin levels in 47 patients with SLE (including eight with MAS) and 7 patients with adult-onset Still’s disease (AOSD) complicated with MAS as a reference population. In neutrophil-based experiments, mRNA expression levels of S100A8 and S100A9 were measured following stimulation with IFN-α or interleukin (IL)-1β. Results: Serum calprotectin levels were significantly elevated in patients with SLE-MAS compared to those with SLE without MAS and comparable to those in patients with AOSD-MAS. Calprotectin levels correlated with serum ferritin levels (rs = 0.49, P = .004), but not with anti-dsDNA antibodies or complement levels. At a cut-off value of 9184.4 ng/ml, serum calprotectin demonstrated sensitivity of 62.5% and specificity of 94.9% for identifying MAS. Recombinant IFN-α2a induced a dose-dependent increase in S100A8 and S100A9 expression in neutrophils, whereas recombinant interleukin-1β had no effect. Pre-treatment with an anti-IFN-α2 neutralising antibody effectively suppressed the IFN-α2a-induced expression of S100A8 and S100A9. Conclusions: Serum calprotectin, upregulated by IFN-α, may serve as a useful biomarker for diagnosing MAS in SLE.Keywords
Funding Information
- JSPS KAKENHI (24K18642 to Y.Y.)
- JSPS KAKENHI (22K08599)
- JSPS KAKENHI (25K12480 to S.M.)
- TSUCHIYA MEMORIAL MEDICAL FOUNDATION
This publication has 29 references indexed in Scilit:
- Circulating Calprotectin (cCLP) in autoimmune diseasesAutoimmunity Reviews, 2023
- Differences and similarities in cytokine profiles of macrophage activation syndrome in systemic lupus erythematosus and adult-onset Still’s diseaseClinical and Experimental Medicine, 2023
- Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven diseaseModern Rheumatology, 2022
- Low‐density granulocytes in systemic autoimmunity and autoinflammationImmunological Reviews, 2022
- Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseasesNature Reviews Immunology, 2022
- Features, Treatment, and Outcomes of Macrophage Activation Syndrome in Childhood‐Onset Systemic Lupus ErythematosusArthritis & Rheumatology, 2018
- 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative InitiativeArthritis & Rheumatology, 2016
- Serum calprotectin—a promising diagnostic marker for adult-onset Still’s diseaseClinical Rheumatology, 2015
- Macrophage activation syndrome in juvenile systemic lupus erythematosus: A multinational multicenter study of thirty‐eight patientsArthritis & Rheumatism, 2009
- Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 casesRheumatology, 2008